Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Debt to equity
Merck & Co., Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 1.2×, up 0.3× from fiscal 2025 (0.9×). Over the past ten years it has ranged from 0.5× (fiscal 2015) to 1.0× (fiscal 2020); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Annual
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.9× | 19.44% |
| FY2024 | 0.7× | (16.96%) |
| FY2023 | 0.9× | 43.41% |
| FY2022 | 0.6× | (22.20%) |
| FY2021 | 0.8× | (19.64%) |
| FY2020 | 1.0× | 14.17% |
| FY2019 | 0.9× | 18.68% |
| FY2018 | 0.7× | 19.28% |
| FY2017 | 0.6× | 2.57% |
| FY2016 | 0.6× | 13.13% |
Quarterly
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 1.2× | 19.73% |
| Mar 2026 | 1.0× | 14.48% |
| Dec 2025 | 0.9× | 15.29% |
| Sep 2025 | 0.8× | 11.21% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.5×
High 1.0×
Ten-year median
0.7×
Current reading's percentile
82
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ABBV AbbVie Inc. compare | −12.0× |
| JNJ Johnson & Johnson compare | 0.4× |
| AZN AstraZeneca PLC compare | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| NVS Novartis AG compare | 1.1× |
| MRK Merck & Co., Inc. | 1.2× |
| GILD Gilead Sciences, Inc. compare | 2.2× |
| AMGN Amgen Inc. compare | 4.9× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement